Clinical Trial

Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study is a multi-indication, open-label, single-treatment arm, parallel-cohort phase II study of enfortumab vedotin in adult participants with advanced or metastatic colorectal cancer (CRC) or hepatocellular carcinoma (HCC) who have been previously treated with one or more lines of systemic therapy.
Protocol Amendment History 10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2024-08-12; most recent amendment 2026-03-31.
Status change: Not Yet Recruiting → Recruiting 2025-03-20
Trial Details
NCT Number NCT06553885
Lead Sponsor H. Lee Moffitt Cancer Center and Research Institute
Collaborators: Astellas Pharma Inc
Conditions Metastatic Colorectal Cancer, Hepatocellular Carcinoma
Enrollment 40 participants
Start Date 2025-04-01
Primary Completion 2029-09 (estimated)
Study Completion 2029-09 (estimated)
Updated on ClinicalTrials.gov 2026-04-01